Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pargeverine is a synthetic antispasmodic drug primarily used for the treatment of smooth muscle spasms in disorders of the gastrointestinal tract (such as irritable bowel syndrome), uterus, and gallbladder. It exhibits a dual mechanism of action by acting as an antagonist at muscarinic acetylcholine receptor and modulating voltage-dependent calcium channel to reduce intracellular calcium levels. This leads to relaxation of smooth muscle and relief from colic pain or spasms. Clinical studies have shown its efficacy in treating moderate-to-severe colic pain of biliary origin and acute intestinal colic pain. Pargeverine may also interact with inflammatory pathways by modulating cytokines such as interleukin-1β[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pargeverine.